TCR-T cells（Fujian Province Tumor Hospita）

TCR-T细胞（福建省肿瘤医院）

Report date: 2023/02/16 20:00:58

Base Information

Drug NameTCR-T cells（Fujian Province Tumor Hospita）
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionCancer/testis antigen 1 modulatorsHLA Class I Histocompatibility Antigen, A-2 alpha Chain inhibitors
TargetsCancer/testis antigen 1HLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFujian Cancer Hospital
China Registration ClassN/A

Develop Information

Active CompaniesFujian Cancer Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A